Long-term open-label vebicorvir for chronic HBV infection: Safety and off-treatment responses

Authors: Yuen, Man-Fung, Fung, Scott, Ma, Xiaoli, Nguyen, Tuan T., Hassanein, Tarek, Hann, Hie-Won, Elkhashab, Magdy, Nahass, Ronald G., Park, James S., Jacobson, Ira M., Ayoub, Walid S., Han, Steven-Huy, Gane, Edward J., Zomorodi, Katie, Yan, Ran, Ma, Julie, Knox, Steven J., Stamm, Luisa M., Bonacini, Maurizio, Weilert, Frank, Ramji, Alnoor, Bennett, Michael, Ravendhran, Natarajan, Chan, Sing, Dieterich, Douglas T., Kwo, Paul Yien, Schiff, Eugene R., Bae, Ho S., Lalezari, Jacob, Agarwal, Kosh, Sulkowski, Mark S.

Source: In JHEP Reports April 2024 6(4)

Safety and efficacy of vebicorvir administered with entecavir in treatment-naïve patients with chronic hepatitis B virus infection

Authors: Sulkowski, Mark S., Agarwal, Kosh, Ma, Xiaoli, Nguyen, Tuan T., Schiff, Eugene R., Hann, Hie-Won L., Dieterich, Douglas T., Nahass, Ronald G., Park, James S., Chan, Sing, Han, Steven-Huy B., Gane, Edward J., Bennett, Michael, Alves, Katia, Evanchik, Marc, Yan, Ran, Huang, Qi, Lopatin, Uri, Colonno, Richard, Ma, Julie, Knox, Steven J., Stamm, Luisa M., Bonacini, Maurizio, Jacobson, Ira M., Ayoub, Walid S., Weilert, Frank, Ravendhran, Natarajan, Ramji, Alnoor, Kwo, Paul Yien, Elkhashab, Magdy, Hassanein, Tarek, Bae, Ho S., Lalezari, Jacob P., Fung, Scott K., Yuen, Man-Fung

Source: In Journal of Hepatology November 2022 77(5):1265-1275

Safety and efficacy of vebicorvir in virologically suppressed patients with chronic hepatitis B virus infection

Authors: Yuen, Man-Fung, Agarwal, Kosh, Ma, Xiaoli, Nguyen, Tuan T., Schiff, Eugene R., Hann, Hie-Won L., Dieterich, Douglas T., Nahass, Ronald G., Park, James S., Chan, Sing, Han, Steven-Huy B., Gane, Edward J., Bennett, Michael, Alves, Katia, Evanchik, Marc, Yan, Ran, Huang, Qi, Lopatin, Uri, Colonno, Richard, Ma, Julie, Knox, Steven J., Stamm, Luisa M., Bonacini, Maurizio, Jacobson, Ira M., Ayoub, Walid S., Weilert, Frank, Ravendhran, Natarajan, Ramji, Alnoor, Kwo, Paul Yien, Elkhashab, Magdy, Hassanein, Tarek, Bae, Ho S., Lalezari, Jacob P., Fung, Scott K., Sulkowski, Mark S.

Source: In Journal of Hepatology September 2022 77(3):642-652

Deeper virologic suppression with the addition of vebicorvir, a first-generation hepatitis B core inhibitor, to entecavir correlates with reduced inflammation and fibrosis-4 index in treatment naïve patients with HBeAg positive chronic hepatitis B

Authors: Sulkowski, Mark S, Fung, Scott K, Ma, Xiaoli, Nguyen, Tuan T, Schiff, Eugene R., Hann, Hie-Won L, Dieterich, Douglas T, Nahass, Ronald G, Park, James S, Chan, Sing, Han, Steven-Huy B, Gane, Edward J, Bennett, Michael, Yan, Ran, Liu, Jieming, Ma, Julie, Knox, Steven J, Stamm, Luisa M, Bonacini, Maurizio, Jacobson, Ira M, Ayoub, Walid S, Weilert, Frank, Ravendhran, Natarajan, Ramji, Alnoor, Kwo, Paul Yien, Elkhashab, Magdy, Hassanein, Tarek, Bae, Ho S, Lalezari, Jacob P, Agarwal, Kosh, Yuen, Man-Fung

Source: Journal of hepatology. 77(S1):S836-S837

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100167262106.0x000001&indx=1&recIds=ETOCvdc_100167262106.0x000001

SAT366 - Deeper virologic suppression with the addition of vebicorvir, a first-generation hepatitis B core inhibitor, to entecavir correlates with reduced inflammation and fibrosis-4 index in treatment naïve patients with HBeAg positive chronic hepatitis B

Authors: Sulkowski, Mark S, Fung, Scott K, Ma, Xiaoli, Nguyen, Tuan T, Schiff, Eugene R., Hann, Hie-Won L, Dieterich, Douglas T, Nahass, Ronald G, Park, James S, Chan, Sing, Han, Steven-Huy B, Gane, Edward J, Bennett, Michael, Yan, Ran, Liu, Jieming, Ma, Julie, Knox, Steven J, Stamm, Luisa M, Bonacini, Maurizio, Jacobson, Ira M, Ayoub, Walid S, Weilert, Frank, Ravendhran, Natarajan, Ramji, Alnoor, Kwo, Paul Yien, Elkhashab, Magdy, Hassanein, Tarek, Bae, Ho S, Lalezari, Jacob P, Agarwal, Kosh, Yuen, Man-Fung

Source: In Journal of Hepatology July 2022 77 Supplement 1:S836-S837

Bone and renal safety profile at 72 weeks after switching to tenofovir alafenamide in chronic hepatitis B patients.

Authors: Lee, Brian T, Chang, Mimi, Lim, Carolina, Bae, Ho S, Fong, Tse‐Ling

Source: JGH Open; Feb2021, Vol. 5 Issue 2, p258-263, 6p

Subject Terms: TENOFOVIR, HEPATITIS B, BONE density

Improvement of bone mineral density and markers of proximal renal tubular function in chronic hepatitis B patients switched from tenofovir disoproxil fumarate to tenofovir alafenamide.

Authors: Fong, Tse‐Ling, Lee, Brian T., Tien, Andy, Chang, Mimi, Lim, Carolina, Ahn, Aiden, Bae, Ho S.

Source: Journal of Viral Hepatitis; May2019, Vol. 26 Issue 5, p561-567, 7p

Subject Terms: CHRONIC hepatitis B, BONE density, BISOPROLOL, RETINOL-binding proteins, GLOMERULAR filtration rate, NEPHROTOXICOLOGY

This result is not displayed to guests.
Login for full access.

This result is not displayed to guests.
Login for full access.